CoronaryAtlas logo
CoronaryAtlas
Apolipoprotein C3
Pathway / Lipid retention & oxidation

Apolipoprotein C3

APOC3protein

ApoC3 on atherogenic remnants attenuates clearance and intensifies subendothelial lipid retention, plaque inflammation, and rupture risk in Type 1 MI.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleAnchors TRL atherogenicity; inhibits lipoprotein lipase; promotes ApoB-lipoprotein retention and plaque inflammation.
Also acts inVascular inflammation, Cap degradation / rupture
Druggability
DruggableYes
Known drugs / candidates3
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000110245

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
37
C — confounder / Type-II
42
A — assay feasibility
72
E — evidence strength
19
T1DI (composite)
7
Specificity differential (R−C)-4.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(9)